Table 3.
Group A | Group B | |
---|---|---|
N. of patients | 13 (37.1%) | 22 (62.9%) |
Outcomes | ||
Need of treatment step-up after anakinra | 7.7% | 4.5% |
Defervescence of fever at 24 h | 100% | 77.3% |
CRP halving at 48 h | 76.9% | 72.7% |
CAA development after anakinra | 0% | 0% |
CRP halving time (days) | 2 (1–2) | 2 (1–3) |
BNP/proBNP halving time (days) | 2.5 (2–3) | 2 (2–4) |
Ejection Fraction normalization time (days) | 2 (2–3) | 3 (2–9) |
Need of ICU admission after anakinra | – | 0% |
ICU admission duration after anakinra | 5 (4–11) | – |
Time to inotrope support halving (days) | 2 (1–3) | – |
MIS-C relapse after anakinra suspension | 0% | 0% |
Side effects | ||
ALT increase during treatment (>2× age range) | 30.8% | 9.1% |
Injection site reaction | – | 4.5% |
All the continuous variables are expressed as median and IQR.